Healthcare Professionals
Solitaire Revascularization Device
Stent Retriever Thrombectomy for Acute Ischemic Stroke
You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic Canada does not review or control the content on the other website, and is not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Healthcare Professionals
Solitaire Revascularization Device
Stent Retriever Thrombectomy for Acute Ischemic Stroke
The Solitaire™ revascularization device, featuring Parametric™ technology, an overlapping stent retriever-based design, restores blood flow and retrieves clots from occluded blood vessels in the brain for patients experiencing ischemic stroke (IS) due to a large intracranial vessel occlusion (LVO).
In fact, the Solitaire device is now indicated to reduce stroke-related disability by showing nearly 70% relative improvement in functional outcomes at 90 days in patients suffering LVO.1
The Solitaire™ Revascularization Device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset.
The Solitaire™ Revascularization Device is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.
The Solitaire device is comprised of a nitinol scaffolding design attached to a pushwire. The Solitaire device is designed to be delivered through a micro catheter, deployed across a clot, and removed along with the clot to enable revascularization of the occluded intracranial vessel.
Unique4,5 overlapping stent retriever-based design allows the device to expand in larger vessels and compress in smaller vessels during deployment and retrieval all while:
Retaining the same effective Parametric design3-5 as the original Solitaire FR and subsequent Solitaire 2 devices, the Solitaire Platinum devices are enhanced with distinctive evenly spaced platinum markers to provide improved visualization6 for accurate alignment and retrieval.
The 4x40 length device simplifies placement with proximal ophthalmic alignment providing complete coverage of the stroke zone from ICA to M2.2
Solitaire Platinum Revascularization Device
View the features and simulated use of the Solitaire Platinum revascularization device.
More information (see more)
Less information (see less)
Review summaries of published studies supporting the use of Solitaire devices for treatment of acute ischemic stroke.
Cello is a trademark of and is manufactured by Fuji Systems Corporation.
510(k) K162539.
Pai S.B., et, al. Microsurgical Anatomy of the Middle Cerebral Artery. Neurology India. June 2005. Vol 53. Issue 2. Keshelava G. et, al. Surgical anatomy of petrous part of the internal carotid artery. Neuroanatomy (2009) 8: 46–48
Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N. Engl. J. Med. Jun 11 2015;372(24):2285-2295.
Medtronic Internal Report FD2815
Medtronic Internal Report FD2601
Medtronic Internal Report TR-NV12692